All Stories

  1. SARS-CoV-2 burden on the floor was associated with COVID-19 cases and outbreaks in two acute care hospitals: a prospective cohort study
  2. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study
  3. Assessing a safety climate tool adapted to address respiratory illnesses in Canadian hospitals
  4. Use of whole genome sequencing to identify low‐frequency mutations in SARS‐CoV‐2 patients treated with remdesivir
  5. Natural Language Processing for Clinical Laboratory Data Repository Systems: Implementation and Evaluation for Respiratory Viruses
  6. The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study
  7. Natural Language Processing for Clinical Laboratory Data Repository Systems: Implementation and Evaluation for Respiratory Viruses (Preprint)
  8. Use of whole genome sequencing to identify low-frequency mutations in COVID-19 patients treated with remdesivir
  9. Severity of Omicron SARS-CoV-2 Infection in Vaccinated and Unvaccinated Residents of Long Term Care Homes
  10. Burden of severe illness associated with laboratory confirmed influenza in adults aged 50–64 years: A rapid review
  11. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study
  12. Frequency of hand hygiene opportunities in patients on a general surgery service
  13. Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital
  14. N o 225-Lignes directrices quant à la prise en charge des patientes en obstétrique chez lesquelles la présence du syndrome respiratoire aigu sévère (SRAS) est soupçonnée ou probable, et des nouveau-nés issus de ces patientes
  15. No. 225-Management Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected or Probable Severe Acute Respiratory Syndrome (SARS)
  16. Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study
  17. Phylogenetic analysis of emergent Streptococcus pneumoniae serotype 22F causing invasive pneumococcal disease using whole genome sequencing
  18. Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05–2013/14, Toronto, Canada
  19. Detecting and quantifying influenza virus with self- versus investigator-collected mid-turbinate nasal swabs
  20. Optimal hand washing technique to minimize bacterial contamination before neuraxial anesthesia: a randomized control trial
  21. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
  22. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients
  23. Active Surveillance for Influenza Reduces but Does Not Eliminate Hospital Exposure to Patients With Influenza
  24. Influenza and rhinovirus viral load and disease severity in upper respiratory tract infections
  25. Rapid Emergence of a New Clone Impacts the Population at Risk and Increases the Incidence of Type emm89 Group A Streptococcus Invasive Disease
  26. Unit-Specific Rates of Hand Hygiene Opportunities in an Acute-Care Hospital
  27. High Incidence of Invasive group A Streptococcal Infections in Remote Indigenous Communities in Northwestern Ontario, Canada.
  28. Serotype Distribution, Population Structure, and Antimicrobial Resistance of Group B Streptococcus Strains Recovered from Colonized Pregnant Women
  29. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for RecurrentClostridium difficileInfection: An Open-Label, Randomized Controlled Trial
  30. Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Strains: An Investigation Into Household Transmission, Risk Factors, and Environmental Contamination
  31. Acquisition of bacteria on health care workers' hands after contact with patient privacy curtains
  32. Capsular Switching and Other Large-Scale Recombination Events in Invasive Sequence Type 1 Group BStreptococcus
  33. Predictors of influenza among older adults in the emergency department
  34. The Effect of Hospital Isolation Precautions on Patient Outcomes and Cost of Care: A Multi-Site, Retrospective, Propensity Score-Matched Cohort Study
  35. Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study
  36. Clonal Complex 17 Group B Streptococcus strains causing invasive disease in neonates and adults originate from the same genetic pool
  37. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  38. Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003–2011
  39. Determinants of Outcome in Hospitalized Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: Results From National Surveillance in Canada, 2008-2012
  40. Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review
  41. What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings?
  42. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers
  43. High Incidence of Invasive Group A Streptococcus Disease Caused by Strains of UncommonemmTypes in Thunder Bay, Ontario, Canada
  44. Vancomycin-Variable Enterococcal Bacteremia
  45. Epidemiological features of influenza in Canadian adult intensive care unit patients
  46. Acceptance of intradermal inactivated influenza vaccines among hospital staff following 2 seasonal vaccination campaigns
  47. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs
  48. Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort
  49. Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, Is Driven by Clonal Sequence Type 459 Strains
  50. Examining Perceptions about Mandatory Influenza Vaccination of Healthcare Workers through Online Comments on News Stories
  51. Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012
  52. Sequence type 1 group B Streptococcus , an emerging cause of invasive disease in adults, evolves by small genetic changes
  53. Middle East respiratory syndrome
  54. Population Structure and Antimicrobial Resistance of Invasive Serotype IV Group B Streptococcus , Toronto, Ontario, Canada
  55. Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Canadian Tertiary Cancer Center Experience
  56. Simulation Study of the Effect of Influenza and Influenza Vaccination on Risk of Acquiring Guillain-Barré Syndrome
  57. Protecting the Frontline: Designing an Infection Prevention Platform for Preventing Emerging Respiratory Viral Illnesses in Healthcare Personnel
  58. Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial
  59. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: A cluster randomized trial
  60. Vancomycin-Variable Enterococci Can Give Rise to Constitutive Resistance during Antibiotic Therapy
  61. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study
  62. Reply to Vanhems et al
  63. In Vitro Activity of New Cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008–2011
  64. Previous Antibiotic Exposure and Antimicrobial Resistance in Invasive Pneumococcal Disease: Results From Prospective Surveillance
  65. External cues to action and influenza vaccination among post-graduate trainee physicians in Toronto, Canada
  66. Reply to Chironda et al
  67. Health care workers, mandatory influenza vaccination policies and the law
  68. A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development
  69. The integration of barcode scanning technology into Canadian public health immunization settings
  70. Influenza vaccination and Guillain-Barré syndrome
  71. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  72. Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences
  73. The Reemergence of Severe Group A Streptococcal Disease: an Evolutionary Perspective
  74. Medusa's Ugly Head Again: From SARS to MERS-CoV
  75. Rate of Healthcare Worker–Patient Interaction and Hand Hygiene Opportunities in an Acute Care Setting
  76. Reducing Antimicrobial Therapy for Asymptomatic Bacteriuria Among Noncatheterized Inpatients: A Proof-of-Concept Study
  77. Characterization of Invasive Group B Streptococcus Strains from the Greater Toronto Area, Canada
  78. Outbreak of Vancomycin-Susceptible Enterococcus faecium Containing the Wild-Type vanA Gene
  79. Vancomycin-Variable Enterococcus faecium: In Vivo Emergence of Vancomycin Resistance in a Vancomycin-Susceptible Isolate
  80. Peripartum outcomes: non-adjuvanted v. adjuvanted H1N1 vaccination
  81. Healthcare-Associated Influenza in Canadian Hospitals from 2006 to 2012
  82. Trends in antiviral therapy of adults hospitalized with influenza in Canada since the end of the 2009 pandemic
  83. Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
  84. The Effect of Gowning on Labor Epidural Catheter Colonization Rate
  85. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011
  86. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012
  87. Complete sequences of a novel blaNDM-1-harbouring plasmid from Providencia rettgeri and an FII-type plasmid from Klebsiella pneumoniae identified in Canada
  88. Understanding the burden of influenza infection among adults in Canadian hospitals: A comparison of the 2009-2010 pandemic season with the prepandemic and postpandemic seasons
  89. In Memoriam
  90. Downstream Impact of Urine Cultures Ordered without Indication at Two Acute Care Teaching Hospitals
  91. Epidemiology and Outcome of Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals
  92. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study
  93. Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus
  94. Indeterminate tcdB using a Clostridium difficile PCR assay: a retrospective cohort study
  95. Prevalence of Colonization and Infection with Methicillin-ResistantStaphylococcus aureusand Vancomycin-ResistantEnterococcusand ofClostridium difficileInfection in Canadian Hospitals
  96. The Occurrence and Impact of Bacterial Organisms Complicating Critical Care Illness Associated With 2009 Influenza A(H1N1) Infection
  97. Contamination of Canadian private drinking water sources with antimicrobial resistant Escherichia coli
  98. Have changing pneumococcal vaccination programmes impacted disease in Ontario?
  99. Efficacy of Admission Screening for Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae
  100. Cardiac complications of influenza infection in 3 adults
  101. Measuring influenza immunization coverage among health care workers in acute care hospitals and continuing care organizations in Canada
  102. Risk Factors for Influenza among Health Care Workers during 2009 Pandemic, Toronto, Ontario, Canada
  103. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009
  104. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant
  105. Behind the mask: Determinants of nurse's adherence to facial protective equipment
  106. An observational study of the hand hygiene initiative: a comparison of preintervention and postintervention outcomes
  107. Statistical estimates of respiratory admissions attributable to seasonal and pandemic influenza for Canada
  108. Disparity in infection control practices for multidrug-resistant Enterobacteriaceae
  109. Maternal Antibiotic Exposure and Risk of Antibiotic Resistance in Neonatal Early-onset Sepsis
  110. Laboratory-Confirmed Pandemic H1N1 Influenza in Hospitalized Adults: Findings from the Canadian Nosocomial Infections Surveillance Program, 2009-2010
  111. Outbreak of Carbapenem-Resistant Enterobacteriaceae Containing blaNDM-1, Ontario, Canada
  112. The Impact of Infection on Population Health: Results of the Ontario Burden of Infectious Diseases Study
  113. A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine
  114. The Social Determinants of Health and Pandemic H1N1 2009 Influenza Severity
  115. Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population
  116. Outbreak of Extended-Spectrum β-Lactamase–producing Klebsiella oxytoca Infections Associated with Contaminated Handwashing Sinks1
  117. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010
  118. Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine
  119. In Vitro Activity Of Ceftaroline And Comparative Agents Against Clinical Isolates Of Streptococcus Pneumoniae Collected From An Ongoing Canada Wide Surveillance Program: 2008 - 2011
  120. Decreased Susceptibility to Noncarbapenem Antimicrobials in Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates in Toronto, Canada
  121. Emergency department visits and infections
  122. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP)
  123. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy a...
  124. Risk of infection following a visit to the emergency department: a cohort study
  125. Seroprevalence of Pandemic Influenza H1N1 in Ontario from January 2009–May 2010
  126. Incidence of Influenza in Healthy Adults and Healthcare Workers: A Systematic Review and Meta-Analysis
  127. Another Look at the Human Papillomavirus Vaccine Experience in Canada
  128. Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study
  129. H1N1 in Pregnancy: A Tertiary Care Centre Experience
  130. Self-Collected Mid-Turbinate Swabs for the Detection of Respiratory Viruses in Adults with Acute Respiratory Illnesses
  131. The role of drinking water in the transmission of antimicrobial-resistant E. coli
  132. Evaluation of Coseasonality of Influenza and Invasive Pneumococcal Disease: Results from Prospective Surveillance
  133. Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in Canada
  134. New Delhi metallo- -lactamase-1: local acquisition in Ontario, Canada, and challenges in detection
  135. A Comparison Of The First And Second Waves Of H1N1-Related Critical Illness In Canada
  136. Prevalent And Incident Bacterial Infections Among Canadian Critically Ill Patients With Influenza A (H1N1) 2009- Preliminary Data
  137. Respiratory illnesses in Canadian health care workers: a pilot study of influenza vaccine and oseltamivir prophylaxis during the 2007/2008 influenza season
  138. Infection prevention and control practices related to Clostridium difficile infection in Canadian acute and long-term care institutions
  139. Systemic Dysregulation of Angiopoietin-1 and -2 in Streptococcal Toxic Shock Syndrome
  140. Distribution of Antiseptic Resistance GenesqacA, qacB, andsmrin Methicillin-Resistant Staphylococcus aureus Isolated in Toronto, Canada, from 2005 to 2009
  141. Novel Mutations in a Patient Isolate of Streptococcus agalactiae with Reduced Penicillin Susceptibility Emerging after Long-Term Oral Suppressive Therapy
  142. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness
  143. Effect of Patterns of Transferring Patients among Healthcare Institutions on Rates of Nosocomial Methicillin-Resistant Staphylococcus aureus Transmission: A Monte Carlo Simulation
  144. New Delhi metallo- -lactamase-1 in Enterobacteriaceae: emerging resistance
  145. 644: Knowledge about H1N1 influenza and the vaccine impacts vaccination uptake among pregnant women
  146. When should a diagnosis of influenza be considered in adults requiring intensive care unit admission? Results of population-based active surveillance in Toronto
  147. Predictors of pandemic influenza infection in adults presenting to two urban emergency departments, Toronto, 2009
  148. Epidemic of Group A Streptococcus M/ emm 59 Causing Invasive Disease in Canada
  149. Respiratory Virus Infection and Risk of Invasive Meningococcal Disease in Central Ontario, Canada
  150. Pandemic (H1N1) 2009: assessing the response
  151. Physicians and hand hygiene practice: a focus group study
  152. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience
  153. Compulsory School-Entry Vaccination Laws and Exemptions: Who Is Opting Out in Ontario and Why Does It Matter?
  154. Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada
  155. Epidemiology of influenza-associated hospitalization in adults, Toronto, 2007/8
  156. Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis
  157. Laboratory diagnosis of 2009 H1N1 influenza A virus
  158. Methicillin-Resistant Staphylococcus aureus Colonization or Infection in Canada: National Surveillance and Changing Epidemiology, 1995–2007
  159. Hypervirulent Clostridium difficile Strains in Hospitalized Patients, Canada1
  160. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates
  161. Photonic Sensors: Towards the Photonic Nose: A Novel Platform for Molecule and Bacteria Identification (Adv. Mater. 12/2010)
  162. Review: Extended-duration chemoprophylaxis with neuraminidase inhibitors prevents symptomatic influenza
  163. Antimicrobial Susceptibilities of Health Care-Associated and Community-Associated Strains of Methicillin-Resistant Staphylococcus aureus from Hospitalized Patients in Canada, 1995 to 2008
  164. Evaluation of Pneumonia Severity and Acute Physiology Scores to Predict ICU Admission and Mortality in Patients Hospitalized for Influenza
  165. Molecular complexity of successive bacterial epidemics deconvoluted by comparative pathogenomics
  166. Focus Group Study of Hand Hygiene Practice among Healthcare Workers in a Teaching Hospital in Toronto, Canada
  167. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada
  168. Health Care–Associated Clostridium difficile Infection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality
  169. High Prevalence of ST131 Isolates Producing CTX-M-15 and CTX-M-14 among Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from Canada
  170. Decreased necrotizing fasciitis capacity caused by a single nucleotide mutation that alters a multiple gene virulence axis
  171. Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.
  172. Pneumococcal Pneumonia: Potential for Diagnosis through a Urinary Metabolic Profile
  173. Detection and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006
  174. Towards the Photonic Nose: A Novel Platform for Molecule and Bacteria Identification
  175. Assessing the Impact of Intravenous Immunoglobulin in the Management of Streptococcal Toxic Shock Syndrome: A Noble but Difficult Quest
  176. Population-Based Surveillance for Invasive Pneumococcal Disease in Homeless Adults in Toronto
  177. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age
  178. Infection with H274Y-positive influenza A (H1N1) is not associated with a change in nasopharyngeal Streptococcus pneumoniae colonization in patients
  179. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008
  180. Characterization of Cefoxitin-Resistant Escherichia coli Isolates from Recreational Beaches and Private Drinking Water in Canada between 2004 and 2006
  181. Influenza estacional en adultos y niños—Diagnóstico, tratamiento, quimioprofilaxis y control de brotes institucionales: Guías de práctica clínica de la Sociedad de Enfermedades Infecciosas de Estados Unidos de América
  182. Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America
  183. Lignes directrices quant à la prise en charge des patientes en obstétrique chez lesquelles la présence du syndrome respiratoire aigu sévère (SRAS) est soupçonnée ou probable, et des nouveau-nés issus de ces patientes
  184. Management Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected or Probable Severe Acute Respiratory Syndrome (SARS)
  185. Health Care–Associated Clostridium difficile Infection in Adults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study
  186. Impact of a Mandatory Infection Control Education Program on Nosocomial Acquisition of Methicillin-ResistantStaphylococcus aureus
  187. Infection control practices related to Clostridium difficile infection in acute care hospitals in Canada
  188. CME Questions
  189. Diagnostic Testing or Empirical Therapy for Patients Hospitalized with Suspected Influenza: What to Do?
  190. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae
  191. The Effect of Universal Influenza Immunization on Mortality and Health Care Use
  192. The individual, environmental, and organizational factors that influence nurses' use of facial protection to prevent occupational transmission of communicable respiratory illness in acute care hospitals
  193. Characterization of Clostridium difficile Strains Isolated from Patients in Ontario, Canada, from 2004 to 2006
  194. Antimalarial Therapy Selection for Quinolone Resistance among Escherichia coli in the Absence of Quinolone Exposure, in Tropical South America
  195. Risk Factors for Methicillin-Resistant Staphylococcus aureus (MRSA) Acquisition in Roommate Contacts of Patients Colonized or Infected With MRSA in an Acute-Care Hospital
  196. Dietary Intake of Elderly Living In Toronto Long-Term Care Facilities: Comparison with the Dietary Reference Intake: Response to Klevay
  197. Reply to Chan‐Tack and Murray
  198. Factors Associated With Acquisition of Vancomycin-Resistant Enterococci (VRE) in Roommate Contacts of Patients Colonized or Infected with VRE in a Tertiary Care Hospital
  199. A Cross-Sectional Study of Maternity Care Providers’ and Women’s Knowledge, Attitudes, and Behaviours Towards Influenza Vaccination During Pregnancy
  200. At the Threshold: Defining Clinically Meaningful Resistance Thresholds for Antibiotic Choice in Community‐Acquired Pneumonia
  201. Impact of public vaccination programs on adult vaccination rates: Two examples from Ontario, Canada
  202. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance
  203. Neonatal group B streptococcal disease: Incidence, presentation, and mortality
  204. Antiviral Therapy and Outcomes of Influenza Requiring Hospitalization in Ontario, Canada
  205. Antivirals and the Control of Influenza Outbreaks
  206. Factors Associated With Critical-Care Healthcare Workers' Adherence to Recommended Barrier Precautions During the Toronto Severe Acute Respiratory Syndrome Outbreak
  207. Dietary Intake of Elderly Living in Toronto Long-Term Care Facilities: Comparison to the Dietary Reference Intake
  208. Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals
  209. RESPONSE LETTER TO DR. HEMILÄ
  210. Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome
  211. ampC gene expression in promoter mutants of cefoxitin-resistant Escherichia coli clinical isolates
  212. Invasive Pneumococcal Disease in Solid Organ Transplant Recipients?10-Year Prospective Population Surveillance
  213. Comparative Genomics of Canadian Epidemic Lineages of Methicillin-Resistant Staphylococcus aureus
  214. Severe Acute Respiratory Syndrome (SARS) Coronavirus
  215. Adverse Events Associated with High-Dose Ribavirin: Evidence from the Toronto Outbreak of Severe Acute Respiratory Syndrome
  216. Alternative Methods of Estimating an Incubation Distribution
  217. Randomized Controlled Trial of Chlorhexidine Gluconate for Washing, Intranasal Mupirocin, and Rifampin and Doxycycline Versus No Treatment for the Eradication of Methicillin-Resistant Staphylococcus aureus Colonization
  218. Appropriate measures of influenza immunization program effectiveness
  219. Effect of Multivitamin and Mineral Supplementation on Episodes of Infection in Nursing Home Residents: A Randomized, Placebo-Controlled Study
  220. Guillain-Barré Syndrome After Influenza Vaccination in Adults
  221. Verification of the IDI-MRSA Assay for Detecting Methicillin-Resistant Staphylococcus aureus in Diverse Specimen Types in a Core Clinical Laboratory Setting
  222. OVERDIAGNOSIS OF ASTHMA AND ITS RELATIONSHIP TO BODY MASS INDEX
  223. Macrolide Resistance in Bacteremic Pneumococcal Disease: Implications for Patient Management
  224. Accuracy of Healthcare Worker Recall and Medical Record Review for Identifying Infectious Exposures to Hospitalized Patients
  225. Suspected transmission of methicillin-resistant Staphylococcus aureus between domestic pets and humans in veterinary clinics and in the household
  226. Cluster of Cases of Severe Acute Respiratory Syndrome Among Toronto Healthcare Workers After Implementation of Infection Control Precautions: A Case Series
  227. An outbreak of methicillin-resistant Staphylococcus aureus skin infections resulting from horse to human transmission in a veterinary hospital
  228. Early diagnosis of SARS: lessons from the Toronto SARS outbreak
  229. Methicillin-Resistant Staphylococcus aureus in Canadian Aboriginal People
  230. Febrile respiratory illness in the intensive care unit setting: an infection control perspective
  231. Viable Group A Streptococci in Macrophages during Acute Soft Tissue Infection
  232. Methicillin-resistant Staphylococcus aureus Colonization in Veterinary Personnel
  233. Coordinated Response to SARS, Vancouver, Canada
  234. A survey of physician's attitudes regarding management of severe group A streptococcal infections
  235. Methicillin-resistant Staphylococcus Aureus in Horses at a Veterinary Teaching Hospital: Frequency, Characterization, and Association with Clinical Disease
  236. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management
  237. Use of a Selective Enrichment Broth To Recover Clostridium difficile from Stool Swabs Stored under Different Conditions
  238. Clinical and Epidemiologic Features of Methicillin-Resistant Staphylococcus aureus in Elderly Hospitalized Patients
  239. Effect of a multifaceted intervention on number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes: cluster randomised controlled trial
  240. Genetic Diversity among Type emm28 Group A Streptococcus Strains Causing Invasive Infections and Pharyngitis
  241. Decreased Prevalence of Virulence Factors among Ciprofloxacin-Resistant Uropathogenic Escherichia coli Isolates
  242. Hospital-Acquired Invasive Group A Streptococcal Infections in Ontario, Canada, 1992-2000
  243. Risk Factors for Pediatric Invasive Group A Streptococcal Disease
  244. Modeling Transmission of Methicillin-Resistant Staphylococcus Aureus Among Patients Admitted to a Hospital
  245. Mosaic Prophages with Horizontally Acquired Genes Account for the Emergence and Diversification of the Globally Disseminated M1T1 Clone of Streptococcus pyogenes
  246. Identification of a Progenitor of the CTX-M-9 Group of Extended-Spectrum β-Lactamases from Kluyvera georgiana Isolated in Guyana
  247. Prevalence and Characterization of Invasive Isolates of Streptococcus pyogenes with Reduced Susceptibility to Fluoroquinolones
  248. Detection of Airborne Severe Acute Respiratory Syndrome (SARS) Coronavirus and Environmental Contamination in SARS Outbreak Units
  249. Predicting Antimicrobial Resistance in Invasive Pneumococcal Infections
  250. Can Routine Laboratory Tests Discriminate between Severe Acute Respiratory Syndrome and Other Causes of Community‐Acquired Pneumonia?
  251. Patient Contact Recall after SARS Exposure
  252. Does isolation prevent the spread of methicillin-resistant Staphylococcus aureus?
  253. Economic Evaluation of Oseltamivir Phosphate for Postexposure Prophylaxis of Influenza in Long-Term Care Facilities
  254. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach
  255. Beliefs and practices of Ontario midwives about influenza immunization
  256. Nosocomial Acquisition of Methicillin-Resistant Staphylococcus aureus During an Outbreak of Severe Acute Respiratory Syndrome
  257. Community-associated methicillin-resistant Staphylococcus aureus in horses and humans who work with horses
  258. Compliance and psychological impact of the quarantine experience during SARS
  259. SARS outbreak in the Greater Toronto Area: the emergency department experience
  260. Adverse Effects of Amantadine and Oseltamivir Used During Respiratory Outbreaks in a Center for Developmentally Disabled Adults
  261. Complete Nucleotide Sequence of a 92-Kilobase Plasmid Harboring the CTX-M-15 Extended-Spectrum Beta-Lactamase Involved in an Outbreak in Long-Term-Care Facilities in Toronto, Canada
  262. In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002
  263. Health Care Workers and the Initiation of Treatment for Latent Tuberculosis Infection
  264. Enterococcus faecium N03-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon
  265. Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections
  266. Let Him Who Desires Peace Prepare for War: United States Hospitals and Severe Acute Respiratory Syndrome Preparedness
  267. Clostridium difficile infection in hospitals: a brewing storm
  268. Nursing Home Residents and Enterobacteriaceae Resistant to Third-Generation Cephalosporins
  269. Transmission and control of SARS
  270. SARS in Healthcare Facilities, Toronto and Taiwan
  271. Hospital Preparedness and SARS
  272. Patterns of Handwashing Behavior and Visits to Patients on a General Medical Ward of Healthcare Workers
  273. News in Antimicrobial Resistance: Documenting the Progress of Pathogens
  274. SARS among Critical Care Nurses, Toronto
  275. Facility-Level Correlates of Antimicrobial Use in Nursing Homes
  276. Severe Invasive Group a Streptococcal Infections
  277. Nutrition Risk Factors for Survival in the Elderly Living in Canadian Long-Term Care Facilities
  278. SARS — One Year Later
  279. Use of, Effectiveness of, and Attitudes Regarding Influenza Vaccine Among House Staff
  280. High Heart Rates at Anaerobic Threshold in Healthy Women
  281. Invasive Group A Streptococcal Disease: Risk Factors for Adults
  282. Emergence of Macrolide Resistance in Throat Culture Isolates of Group A Streptococci in Ontario, Canada, in 2001
  283. Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae : Redefining Fluoroquinolone Resistance
  284. Identification of Severe Acute Respiratory Syndrome in Canada
  285. Is resistance futile?
  286. Clinical manifestations associated with the aberrant expression of the soluble granulocyte-macrophage colony-stimulating factor receptor in patients presenting with haematological malignancies
  287. Clinical and Epidemiologic Features of Group A Streptococcal Pneumonia in Ontario, Canada
  288. Association of Human Leukocyte Antigen with Outcomes of Infectious Diseases: The Streptococcal Experience
  289. Risk Factors for Resistance to Antimicrobial Agents among Nursing Home Residents
  290. Prospective Surveillance for Primary Bloodstream Infections Occurring in Canadian Hemodialysis Units
  291. Microbiologic findings and risk factors for antimicrobial resistance at myringotomy for tympanostomy tube placement—a prospective study of 601 children in Toronto
  292. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections
  293. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections
  294. Prevention of Invasive Group A Streptococcal Disease among Household Contacts of Case Patients and among Postpartum and Postsurgical Patients: Recommendations from the Centers for Disease Control and Prevention
  295. Laboratory Characterization of Methicillin‐Resistant Staphylococcus aureus in Canadian Hospitals: Results of 5 Years of National Surveillance, 1995–1999
  296. Clinical aspects and cost of invasive Streptococcus pneumoniae infections in children: resistant vs. susceptible strains
  297. Laboratory Contamination of Specimens with Quality Control Strains of Vancomycin-Resistant Enterococci in Ontario
  298. Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000
  299. Activities of New Fluoroquinolones, Ketolides, and Other Antimicrobials against Blood Culture Isolates of Viridans Group Streptococci from across Canada, 2000
  300. Activity of BMS-284756, a Novel Des-Fluoro(6) Quinolone, against Staphylococcus aureus, Including Contributions of Mutations to Quinolone Resistance
  301. Use of Oseltamivir During Influenza Outbreaks in Ontario Nursing Homes, 1999–2000
  302. Severe Group A Streptococcal Soft-Tissue Infections in Ontario: 1992-1996
  303. Quality and methods of developing practice guidelines
  304. Exploring the Pathogenesis of Necrotizing Fasciitis Due to Streptococcus pneumoniae
  305. Annualized Incidence and Spectrum of Illness from an Outbreak Investigation of Bell’s Palsy
  306. Prevalence and Mechanisms of Macrolide Resistance in Invasive and Noninvasive Group B Streptococcus Isolates from Ontario, Canada
  307. Evidence for Superantigen Involvement in Severe Group A Streptococcal Tissue Infections
  308. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home
  309. Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals
  310. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation
  311. A Nosocomial Outbreak of Fluoroquinolone‐Resistant Streptococcus pneumoniae
  312. Identifying research priorities on infections in older adults: proceedings of an interdisciplinary workshop
  313. Antibodies to Capsular Polysaccharides of Group B Streptococcus in Pregnant Canadian Women: Relationship to Colonization Status and Infection in the Neonate
  314. Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae
  315. Antibiotic use in ontario facilities that provide chronic care
  316. Oropharyngeal Candidiasis in Patients with Human Immunodeficiency Virus: Correlation of Clinical Outcome with In Vitro Resistance, Serum Azole Levels, and Immunosuppression
  317. A 2 factor model helped to rule out early stage necrotising fasciitis
  318. A RANDOMIZED TRIAL TO MEASURE THE OPTIMAL ROLE OF THE PHARMACIST IN PROMOTING EVIDENCE-BASED ANTIBIOTIC USE IN ACUTE CARE HOSPITALS
  319. A Blinded Comparison of Three Laboratory Protocols for the Identification of Patients Colonized With Methicillin-Resistant Staphylococcus aureus
  320. Development of Minimum Criteria for the Initiation of Antibiotics in Residents of Long-Term–Care Facilities: Results of a Consensus Conference
  321. The Nature and Frequency of Blood Contacts Among Home Healthcare Workers
  322. Inverse Relation between Disease Severity and Expression of the Streptococcal Cysteine Protease, SpeB, among Clonal M1T1 Isolates Recovered from Invasive Group A Streptococcal Infection Cases
  323. Zanamivir Use During Transmission of Amantadine-Resistant Influenza A in a Nursing Home
  324. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection
  325. Etiology of community-acquired pediatric viral diarrhea: a prospective longitudinal study in hospitals, emergency departments, pediatric practices and child care centers during the winter rotavirus outbreak, 1997 to 1998
  326. Genetic Relatedness and Superantigen Expression in Group A Streptococcus Serotype M1 Isolates from Patients with Severe and Nonsevere Invasive Diseases
  327. Cigarette Smoking and Invasive Pneumococcal Disease
  328. A Comparison of Model-Building Strategies for Lower Respiratory Tract Infection in Long-Term Care
  329. Prevention of Neural-Tube Defects
  330. CLINICAL UTILITY OF QUANTITATIVE CYTOMEGALOVIRUS VIRAL LOAD DETERMINATION FOR PREDICTING CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1
  331. Molecular Characterization of a Nosocomial Outbreak of Human Respiratory Syncytial Virus on an Adult Leukemia/Lymphoma Ward
  332. Two-year survey of Alberta laboratories processing of antenatal group B streptococcal (GBS) screening specimens: implications for GBS screening programs
  333. Risk Factors for Pneumonia and Other Lower Respiratory Tract Infections in Elderly Residents of Long-term Care Facilities
  334. Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
  335. Influenza Vaccination in Long-Term–Care Facilities: Structuring Programs for Success
  336. Practical approach to the identification of clinically relevant Enterococcus species
  337. Clinical Experience with 20 Cases of Group A Streptococcus Necrotizing Fasciitis and Myonecrosis: 1995 to 1997
  338. Clinical Experience with 20 Cases of Group A Streptococcus Necrotizing Fasciitis and Myonecrosis: 1995 to 1997
  339. Control of Transmission of Vancomycin-Resistant Enterococcus faecium in a Long-Term–Care Facility
  340. Intravenous Immunoglobulin Therapy for Streptococcal Toxic Shock Syndrome—A Comparative Observational Study
  341. Elevated Serum Cytokines Are Associated with Cytomegalovirus Infection and Disease in Bone Marrow Transplant Recipients
  342. Skin and soft tissue infection
  343. The rapid emergence of a new strain of MRSA in Ontario: Laboratory implications
  344. The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease
  345. Effect of Cytomegalovirus Infection on 1‐Year Mortality Rates Among Recipients of Allogeneic Bone Marrow Transplants
  346. Varying Titers of Neutralizing Antibodies to Streptococcal Superantigens in Different Preparations of Normal Polyspecific Immunoglobulin G: Implications for Therapeutic Efficacy
  347. Can pregnant women obtain their own specimens for group B streptococcus? A comparison of maternal versus physician screening. The Mount Sinai GBS Screening Group
  348. Invasive Infections Due to a Fish Pathogen, Streptococcus iniae
  349. Population-Based Surveillance for Group A Streptococcal Necrotizing Fasciitis: Clinical Features, Prognostic Indicators, and Microbiologic Analysis of Seventy-Seven Cases
  350. Invasive Group A Streptococcal Infections
  351. Novel Superantigens from Streptococcal Toxic Shock Syndrome Streptococcus pyogenes Isolates
  352. Superantigenic Activity Produced by Group A Streptococcal Isolates is Neutralized by Plasma from IVIG-Treated Streptococcal Toxic Shock Snydrome Patients
  353. Invasive Group A Streptococcal Infections in Ontario, Canada
  354. Tuberculosis Surveillance Practices in Long-Term Care Institutions
  355. Tuberculosis Surveillance Practices in Long-Term Care Institutions
  356. Pharmacoeconomic Analysis of Empirical Therapy with Ceftazidime Alone or Combination Antibiotics for Febrile Neutropenia in Cancer Patients
  357. Influenza and Pneumococcal Vaccination and Tuberculin Skin Testing Programs in Long-Term Care Facilities: Where Do We Stand?
  358. Influenza and Pneumococcal Vaccination and Tuberculin Skin Testing Programs in Long-Term Care Facilities: Where Do We Stand?
  359. HIV-Associated Lymphoma of the Gastrointestinal Tract: The University of Toronto AIDS-Lymphoma Study Group Experience
  360. Diagnosis of Whipple's Disease by Molecular Analysis of Peripheral Blood
  361. The Use of Molecular Typing Techniques in the Epidemiologic Investigation of Resistant Enterococci
  362. The Use of Molecular Typing Techniques in the Epidemiologic Investigation of Resistant Enterococci
  363. Human Immunodeficiency Virus Transmission Between Surgeons and Patients in Orthopaedic Surgery
  364. Recent advances in the management of infections in cancer patients
  365. A Cluster of Surgical Wound Infections Due to Unrelated Strains of Group a Streptococci
  366. Reliability of interpretation of tuberculin testing in the elderly: Implications for practice
  367. Incorporating variations in the quality of individual randomized trials into meta-analysis
  368. Mechanisms of Glove Tears and Sharp Injuries Among Surgical Personnel
  369. Effect of an Automated Sink on Handwashing Practices and Attitudes in High-Risk Units
  370. Effect of an Automated Sink on Handwashing Practices and Attitudes in High-Risk Units
  371. Definitions of infections
  372. Identification and management of salmonellosis in a newborn nursery
  373. Antibiotic prescribing patterns in long-term care facilities (LTCFs)
  374. Body temperature variation in elderly residents of long-term care facilities (LTCFs)
  375. Definitions of infection for surveillance in long-term care facilities
  376. Epidemiology of Needlestick Injuries in House Officers
  377. Surveillance for Quality Assessment: II. Surveillance for Noninfectious Processes: Back to Basics
  378. Surveillance for Quality Assessment: II. Surveillance for Noninfectious Processes: Back to Basics
  379. The buffering capacity of the internal phase of thylakoids and the magnitude of the pH changes inside under flashing light
  380. CALIBRATION OF FLASH INDUCED pH CHANGES INSIDE THYLAKOIDS AND KINETIC RESOLUTION OF PROTON EJECTION AND CONSUMPTION
  381. Terminal Cross-linking of DNA Catalyzed by an Enzyme System Containing DNA Ligase, DNA Polymerase, and Exonuclease of Bacteriophage T7
  382. The Effect of Universal Influenza Immunization on Mortality and Health Care Use